Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $60.89.

Several equities analysts have recently weighed in on the company. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th.

Halozyme Therapeutics Stock Up 0.5 %

Halozyme Therapeutics stock opened at $57.94 on Friday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 1-year low of $34.36 and a 1-year high of $65.53. The company has a fifty day simple moving average of $51.18 and a 200 day simple moving average of $54.38. The company has a market cap of $7.37 billion, a P/E ratio of 19.19, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. GAMMA Investing LLC lifted its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the period. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the third quarter worth $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.